Media stories about Masimo Corporation (NASDAQ:MASI) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Masimo Corporation earned a news impact score of 0.17 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 47.1328621753027 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Columbia Wanger Asset Management LLC Significantly Increases Its Ownership in Masimo Corporation (MASI) Stock (highlightpress.com)
- MASI Beat Estimates, Then Dropped Like A Rock (seekingalpha.com)
- Masimo Corporation (MASI) & Entellus Medical (ENTL) Financial Comparison (americanbankingnews.com)
- Old Mutual Global Investors (uk) Ltd. Buys A Lot More Masimo Corporation (MASI) Stock In The Last Quarter (highlightpress.com)
- Masimo (MASI) Shares Cross Below 200 DMA (nasdaq.com)
MASI has been the subject of several recent research reports. Zacks Investment Research lowered shares of Masimo Corporation from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 11th. Wedbush reissued an “outperform” rating and issued a $112.00 price target on shares of Masimo Corporation in a research report on Monday, May 22nd. BidaskClub lowered shares of Masimo Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Stifel Nicolaus initiated coverage on shares of Masimo Corporation in a research report on Monday, July 10th. They issued a “buy” rating and a $105.00 price target for the company. Finally, Roth Capital increased their price target on shares of Masimo Corporation from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Wednesday, July 19th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $94.00.
Shares of Masimo Corporation (NASDAQ MASI) opened at 83.58 on Friday. The stock’s 50 day moving average is $92.27 and its 200 day moving average is $89.85. The firm has a market cap of $4.34 billion, a price-to-earnings ratio of 13.70 and a beta of 0.80. Masimo Corporation has a 12-month low of $53.78 and a 12-month high of $104.71.
Masimo Corporation (NASDAQ:MASI) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.71 by $0.12. The firm had revenue of $192.90 million during the quarter, compared to the consensus estimate of $189.03 million. Masimo Corporation had a net margin of 45.90% and a return on equity of 23.45%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.57 EPS. Equities analysts expect that Masimo Corporation will post $2.80 earnings per share for the current year.
In other Masimo Corporation news, insider Jon Coleman sold 25,000 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $97.50, for a total value of $2,437,500.00. Following the completion of the sale, the insider now owns 32,201 shares of the company’s stock, valued at approximately $3,139,597.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Anand Sampath sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The stock was sold at an average price of $92.00, for a total transaction of $3,680,000.00. Following the sale, the chief operating officer now directly owns 20,000 shares of the company’s stock, valued at approximately $1,840,000. The disclosure for this sale can be found here. Insiders sold a total of 115,000 shares of company stock valued at $10,773,180 in the last three months. Insiders own 16.60% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2017/08/12/masimo-corporation-masi-earns-news-sentiment-score-of-0-17.html.
Masimo Corporation Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
What are top analysts saying about Masimo Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Masimo Corporation and related companies.